Off-target toxicity has killed off one of Bolt Biotherapeutics’ lead programs. Rather than push BDC-2034 into the clinic, the immuno-oncology startup is winding down spending on the anti-tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results